Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma

PURPOSE: Ramucirumab was shown to be effective as a second-line treatment after sorafenib in patients with advanced hepatocellular carcinoma (HCC) with alpha-fetoprotein levels > 400 ng/mL in a worldwide phase 3 trial. Ramucirumab is used in patients pretreated with various systemic therapies in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanogawa, Naoya, Ogasawara, Sadahisa, Maruta, Susumu, Iino, Yotaro, Obu, Masamichi, Ishino, Takamasa, Ogawa, Keita, Yumita, Sae, Iwanaga, Terunao, Unozawa, Hidemi, Nakagawa, Miyuki, Fujiwara, Kisako, Sakuma, Takafumi, Fujita, Naoto, Kojima, Ryuta, Kanzaki, Hiroaki, Koroki, Keisuke, Kobayashi, Kazufumi, Inoue, Masanori, Kiyono, Soichiro, Nakamura, Masato, Kondo, Takayuki, Saito, Tomoko, Nakagawa, Ryo, Nakamoto, Shingo, Muroyama, Ryosuke, Chiba, Tetsuhiro, Itobayashi, Ei, Koma, Yoshihiro, Azemoto, Ryosaku, Kato, Jun, Kato, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007811/
https://www.ncbi.nlm.nih.gov/pubmed/36906542
http://dx.doi.org/10.1186/s12876-023-02674-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007811/
https://www.ncbi.nlm.nih.gov/pubmed/36906542
http://dx.doi.org/10.1186/s12876-023-02674-x

Ejemplares similares